IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Abbott Medical Optics, Inc. v Alcon Laboratories, Inc. [2011] APO 79
Opponent:Abbott Medical Optics, Inc.
Delegate:Dr B. Akhurst
Decision Date: 26 September 2011
Hearing Date: 7 October 2010 and 11 May 2011 in Canberra, then completed by further written submissions filed on 30 August 2011 and 6 September 2011.
Catchwords: PATENTS - section 59 - opposition to the grant of a patent - claims construction - novelty - claims lack novelty over prior published information - claims lack novelty in light of the prior use of a product in accordance with the manufacturer’s instructions - strict proof requirement - inventive step - claims lack inventive step over published prior art - clarity in view of typographical error - opposition succeeds on the grounds of novelty, inventive step and clarity.
Representation: Patent applicant: Glenn McGowan SC, instructed by patent attorney Dr Simon Weisman of FB Rice & Co., Sydney.
Opponent:Dr Linda Govenlock (Senior Associate) and Dr Trevor Davies (Partner), patent attorneys of Allens Arthur Robinson, Sydney.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2004201867
Title: Process for cleaning and disinfecting contact lenses
Patent Applicant: Alcon Laboratories, Inc.
Date of Decision: 26 September 2011
DECISION
The opposition succeeds. The subject matter of claims 1-5, 9 and 11-17 is not novel. Claims 1 and 2 lack an inventive step. Claim 20 is not clear. The amendments to the claims filed under section 104 on 11 May 2011 are similarly deficient. Alcon is allowed 2 months to file amendments to overcome the deficiencies in the claims. Costs are awarded against Alcon Laboratories, Inc.
REASONS FOR DECISION
Background
Patent application 2004201867 was filed by Alcon Laboratories, Inc (‘Alcon’) on 30 April 2004, as one of a series of divisional applications derived from application 76730/94 and claiming priority from US basic document 08/113,142 filed on 27 August 1993. The related applications are listed below, with subsequent applications each divided from the one above.
Application No Filing date Status
76730/94 24 August 1994 Lapsed
71874/98 11 June 1998 Sealed as patent No. 733386
54175/01 2 July 2001 Lapsed
2004201867 30 April 2004 Accepted
2011202183 11 May 2011 Filed
Application 2004201867 was advertised accepted on 3 January 2008. A notice of opposition to grant of a patent was filed on 2 April 2008 by Advanced Medical Optics, Inc., followed by a statement of grounds and particulars on 2 July 2008. On 16 September 2009, the notice of opposition was amended under regulation 5.3B to change the name of the opponent to Abbott Medical Optics, Inc. (‘Abbott’).
Abbott filed no evidence in support despite gaining an extension of 3 months to 2 January 2009 in which to do so.
Evidence in answer was served on 2 November 2009, consisting of statutory declarations by
· Dr Masood Chowhan dated 26 October 2009 (Chowhan#1), and
· Dr Howard Ketelson dated 26 October 2009.
Evidence in reply was completed on 30 April 2010, consisting of statutory declarations by
· Dr Linda Jane Govenlock dated 1 February 2010…
Keep reading for free
Create a free CaseChat account to read Abbott Medical Optics, Inc. v Alcon Laboratories, Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2011] APO 79
- Decision Date
CaseChat Overview and Summary
The court first constricted the claims, focusing on claims 1 and 2, which defined the scope of the patent. The court found that claims 1 and 2 lacked novelty, as they were anticipated by prior publications and prior use of Opti-Free® Rinsing, Disinfecting and Storage Solution. The court also found that claims 1 and 2 lacked an inventive step over the prior art. The court found that claim 20 was unclear due to a typographical error in the concentration of sodium citrate.
The court concluded that Abbott had succeeded in its opposition, and the patent grant was not valid. The court allowed Alcon two months to propose amendments to the claims to overcome the deficiencies identified. Costs were awarded against Alcon Laboratories, Inc., as the opposition proceedings had been prolonged by the conduct of both parties.
Background
Background to the litigation
The patent application 2004201867 was filed by Alcon Laboratories, Inc. on 30 April 2004. The application was one of a series of divisional applications derived from an earlier application. Abbott filed a notice of opposition on 2 April 2008, followed by a statement of grounds and particulars on 2 July 2008. The opposition hearing took place in two parts: on 7 October 2010 and 11 May 2011 in Canberra. Further written submissions were filed by both parties after the second hearing. The hearing was concluded by additional written submissions on 30 August 2011 and 6 September 2011. The decision was issued on 26 September 2011.
Decision
Reasons for decision
1. Whether the subject matter of claims 1-5, 9 and 11-17 of the patent application is novel over the prior art.
2. Whether the subject matter of claims 1 and 2 of the patent application lacks an inventive step over the prior art.
3. Whether the subject matter of claim 20 of the patent application is clear.
4. Whether the patent claims are fairly based on the matter described in the specification.
Held
1. The opposition to the grant of the patent was successful.
2. The subject matter of claims 1-5, 9 and 11-17 of the patent application is not novel.
3. The subject matter of claims 1 and 2 of the patent application lacks an inventive step.
4. Claim 20 of the patent application is not clear.
5. The amendments to the claims filed under section 104 on 11 May 2011 are similarly deficient.
6. The patent applicant, Alcon Laboratories, Inc., is allowed 2 months to file amendments to overcome the deficiencies in the claims.
7. Costs are awarded against Alcon Laboratories, Inc.
Ratio Decidendi
Legal Principle Established
In this case, the court was tasked with determining whether the patent application met the criteria for novelty, inventive step, clarity, and fair basis under Australian patent law. The opposition was brought by Abbott Medical Optics, Inc. against Alcon Laboratories, Inc., the patent applicant. The court examined the patent claims in light of prior art and the content of the specification.
The court first considered the issue of novelty, determining that claims 1-5, 9, and 11-17 were anticipated by prior art, including the Opti-Free® RDS package insert, which contained instructions for using the Opti-Free® Rinsing, Disinfecting and Storage Solution. The package insert provided a method that inevitably led to the claimed invention, involving the use of a single solution to clean and disinfect contact lenses.
Regarding the inventive step, the court found that claims 1 and 2 lacked an inventive step in light of the prior art documents US'195 and US'239. These documents disclosed methods for cleaning contact lenses using solutions that included polycarboxylic acids, which was known prior to the priority date. However, claims 3-21 were found to involve an inventive step as they were not suggested by the prior art.
The court also examined the clarity of the claims. While claims 1-19 and 21 were found to be clear, claim 20 was deemed unclear due to a typographical error that resulted in a concentration of citric acid that was less than the effective amount required.
Finally, the court assessed whether the claims were fairly based on the matter described in the specification. The court concluded that the claims were fairly based as the specification provided a real and reasonably clear disclosure of the claimed invention.
In conclusion, the opposition was successful on the grounds of novelty, inventive step, and clarity. Alcon was granted two months to file amended claims to overcome the deficiencies identified by the court. Costs were awarded against Alcon Laboratories, Inc.